Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing usage of psychoactive substances and narcotic drugs
3.2.1.2 Rising expenditure on the R&D of novel treatments
3.2.1.3 Increase in awareness regarding preventive poisoning
3.2.2 Industry pitfalls & challenges
3.2.2.1 Complications and adverse drug events related to medications
3.3 Growth potential analysis
3.4 Porter's analysis
3.4.1 Supplier power
3.4.2 Buyer power
3.4.3 Threat of new entrants
3.4.4 Threat of substitutes
3.4.5 Industry rivalry
3.5 PESTEL analysis
3.6 List of APIs used in alexipharmic drugs
3.7 Analysis of API manufacturers
3.8 Reimburesemnt scenario
3.9 Regulatory landscape
3.10 Technological landscape
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Application, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Opioid overdose
5.3 Alcohol overdose
5.4 Cyanide poisoning
5.5 Lead poisoning
5.6 Benzodiazepine overdose
5.7 Other applications
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Injectable
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies
Chapter 8 Market Estimates and Forecast, By End-Use, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital
8.3 Homecare
8.4 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AdvaCare Pharma
10.2 American Regent, Inc.
10.3 B. Braun Melsungen AG
10.4 Bausch Health Companies Inc
10.5 Fresenius SE & Co. KGaA
10.6 Intelicure Lifesciences
10.7 Merck KGaA
10.8 Mylan N.V.
10.9 SimSon Pharma Limited
10.10 Thermo Fisher Scientific Inc.
